country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-P99264A

Copy Link Print Information

Inotuzumab (powder)

(Synonyms: Humanized Anti-CD22 Recombinant Antibody (powder))

1 Cited Publications

고객리뷰

Based on 1 publication(s) in Google Scholar

Inotuzumab (Humanized Anti-CD22 Recombinant Antibody) (powder) is a humanized IgG4κ antibody that targets human CD22. Inotuzumab (powder) can be linked to a toxic agent Ozogamicin as an antibody-drug conjugate (ADC), Inotuzumab ozogamicin (HY-P9959). Inotuzumab (powder) can be used for the research of acute lymphoblastic leukemia and non-Hodgkin lymphoma.

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

CAS No.: 1660159-36-3
분자량:146.48 kDa

보관:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (261 KB)

Inotuzumab (powder) Chemical Structure

CAS No.: 1660159-36-3

사이즈

가격

재고

수량

Amount: USD 0.00

* 장바구니에 담기 전 물품의 수량을 선택해 주십시오.

Top Publications Citing

Use of MCE Products

One-stop CDMO Service

One-Stop Platform：From Independent R&D to Pilot-Scale Production

Biological Activity
- 제품 설명
- Isotype
- Recommend Isotype Controls
- Species Reactivity
- In Vitro
- In Vivo
- Gene ID
- Accession
- Conjugated
- Reconsititution
- Format
- 신청
Chemical Information
Publications (1)
순도&문서
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

제품 설명

Isotype

Human IgG4 kappa

Recommend Isotype Controls

Human IgG4 (S228P) kappa, Isotype Control

Species Reactivity

Human

In Vitro

Inotuzumab ozogamicin (100, 1000 ng/mL, 6 h) induces apoptosis in acute lymphoblastic leukemia (ALL) cells^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Inotuzumab ozogamicin (100 μg/kg, i.p., twice a week for 2 weeks) combined with Venetoclax (HY-15531), Dexamethasone (HY-14648) induces long-term survival in murine patient-derived xenograft (PDX) models^[3].
Inotuzumab (0.27, 3.2 mg/kg, i.p., a single dose for 400 h) (powder) inhibits tumor growth in mouse xenograft models^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Mouse xenograft models^[4].
Dosage:

0.27, 3.2 mg/kg
Administration:

i.p., a single dose for 400 h
Result:

Decreased the tumor volume in mouse xenograft models.

Gene ID

933 [NCBI]

Accession

P20273

Conjugated

Unconjugated

Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.

Format

IgG4-kappa

신청

ELISA, FACS, Functional assay

Chemical Information

CAS No. 1660159-36-3
분자량 146.48 kDa
SMILES

[Inotuzumab (powder)]
Synonyms

Humanized Anti-CD22 Recombinant Antibody (powder)
Formulation

Please refer to the lot-specific COA for specific buffer information.
보관

Please store the product under the recommended conditions in the Certificate of Analysis.

Publications (1)

All

Sort by:

Journal Impact Factor

bioRxiv

2026 May 27.

순도&문서

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (261 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Inhibitory Antibodies User Guide (603 KB)

References

[1]. Aujla A, et al. Inotuzumab ozogamicin in clinical development for acute lymphoblastic leukemia and non-Hodgkin lymphoma. Biomark Res. 2019 Apr 11;7:9. [Content Brief]

[2]. Wynne J, et al. Inotuzumab: from preclinical development to success in B-cell acute lymphoblastic leukemia. Blood Adv. 2019 Jan 8;3(1):96-104. [Content Brief]

[3]. Kirchhoff H, et al. Venetoclax and dexamethasone synergize with inotuzumab ozogamicin-induced DNA damage signaling in B-lineage ALL. Blood. 2021 May 13;137(19):2657-2661. [Content Brief]

[4]. Betts AM, et al. Preclinical to Clinical Translation of Antibody-Drug Conjugates Using PK/PD Modeling: a Retrospective Analysis of Inotuzumab Ozogamicin. AAPS J. 2016 Sep;18(5):1101-1116. [Content Brief]

Calculators

몰농도 계산기

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

농도 희석 계산기

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

Inotuzumab (powder)

1 Cited Publications

100 mg 견적 받기

Subscribe to the

MedChemExpress

Newsletter

MOQ

Minimum order quantity

100 mg

견적 받기 해외재고보유

Other size

견적 받기

Amount: USD 0.00

Biological Activity
- 제품 설명
- Isotype
- Recommend Isotype Controls
- Species Reactivity
- In Vitro
- In Vivo
- Gene ID
- Accession
- Conjugated
- Reconsititution
- Format
- 신청
Chemical Information
Publications (1)
순도&문서
References

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent:

상품명:
CAS No.:
Species:
Purity:
수량:

Inotuzumab (powder)

Publications Citing Use of MedChemExpress (MCE) Inotuzumab (powder)

Biological Activity

Chemical Information

Publications (1)

순도&문서

References

Calculators

Help & FAQs

Inotuzumab (powder) Related Classifications

HY-P99264A Related Classifications